Cover Image
市場調查報告書

Idera Pharmaceuticals, Inc. - 產品平台分析

Idera Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 214162
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
Idera Pharmaceuticals, Inc. - 產品平台分析 Idera Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年05月27日 內容資訊: 英文 44 Pages
簡介

Idera Pharmaceuticals, Inc.是挖掘、開發自體免疫疾病及發炎疾病等治療藥候補的臨床階段專業生物企業。其所開發以治療傳染性疾病用類鐸受體為標的的DNA及RNA型藥劑候補也活用於疫苗的輔助藥中。

本報告提供Idera Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Idera Pharmaceuticals, Inc.的基本資料

Idera Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Idera Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Idera Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Idera Pharmaceuticals, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
  • IND/CTA Filed Products/Combination Treatment Modalities
    • 前臨床階段的產品/聯合治療模式

Idera Pharmaceuticals, Inc.:藥物簡介

  • IMO-3100
  • IMO-8400
  • IMO-2055
  • GSO Compunds
  • IMO-4200
  • IMO-9200
  • TLR3 Agonist

Idera Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Idera Pharmaceuticals, Inc.:最近的開發平台趨勢

Idera Pharmaceuticals, Inc.:暫停中的計劃

Idera Pharmaceuticals, Inc.:開發中止的開發平台

產品 ▼開發中止的開發中產品簡介 ▼IMO-2055 ▼IMO-2125

Idera Pharmaceuticals, Inc.:企業發表

Idera Pharmaceuticals, Inc.:總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07115CDB

Summary

Global Markets Direct's, 'Idera Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Idera Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Idera Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Idera Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Idera Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Idera Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Idera Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Idera Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Idera Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Idera Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Idera Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Idera Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Idera Pharmaceuticals, Inc. Snapshot
    • Idera Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Idera Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Idera Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Idera Pharmaceuticals, Inc. - Pipeline Products Glance
    • Idera Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Idera Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Idera Pharmaceuticals, Inc. - Drug Profiles
    • IMO-8400
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMO-9200
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit miR-21 for Colon Carcinoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotides for Genetic Disorder and Cardiovascular Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMO-2055
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMO-2125
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMO-4200
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotides to Agonize TLR3 for Infectious Disease and Immunology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Idera Pharmaceuticals, Inc. - Pipeline Analysis
    • Idera Pharmaceuticals, Inc. - Pipeline Products by Target
    • Idera Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Idera Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Idera Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Idera Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Idera Pharmaceuticals, Inc. - Dormant Projects
  • Idera Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • IMO-2055
      • IMO-2125
  • Idera Pharmaceuticals, Inc. - Company Statement
  • Idera Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Idera Pharmaceuticals, Inc., Key Information
  • Idera Pharmaceuticals, Inc., Key Facts
  • Idera Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Idera Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Idera Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Idera Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Idera Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Idera Pharmaceuticals, Inc. - Phase II, 2015
  • Idera Pharmaceuticals, Inc. - Phase I, 2015
  • Idera Pharmaceuticals, Inc. - Preclinical, 2015
  • Idera Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Idera Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Idera Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Idera Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Idera Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Idera Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • Idera Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015

List of Figures

  • Idera Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Idera Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Idera Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Idera Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Idera Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Idera Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Idera Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top